San Diego, CA, January 13, 2022 — Objective, Investment Banking & Valuation, a leading middle market investment banking and valuation firm, is pleased to announce that it served as the exclusive sell-side financial advisor to Rocky Mountain Movement Disorders Center (“CenExel RMCR”) in its sale of its clinical research site operations to CenExel Clinical Research, Inc. (“CenExel”). CenExel RMCR is a leading movement disorders-focused research facility with a portfolio of clinical trial studies exceeding 100 trials that primarily serve neurological conditions including Parkinson’s Disease, Huntington’s Disease, Essential Tremor, and other movement disorders. The acquisition of CenExel RMCR supplements CenExel’s leading central nervous system (“CNS”) trial capabilities and further strengthens CenExcel’s Neurology indication capabilities.
CenExel RMCR serves one of the largest communities of patients with Parkinson’s disease and other movement disorders in Colorado. The company offers comprehensive and customized treatment plans for their patients to have the highest quality of life.
The CenExel Centers of Excellence network now comprises 13 of the most accomplished clinical research sites in the United States, with concentration on Neurology, Pain, Psychiatry, Vaccines/Immunology, Dermatology, Ethnic-bridging, Sleep studies, and Clinical Pharmacology. Each of the CenExel research units has an outstanding record of excellence assisting pharmaceutical sponsors with protocol development, study design, and conducting Phase I-IV trials to develop new therapeutics for improved patient care.
“CenExel RMCR has improved the lives of numerous individuals who have been impacted by neurological conditions such as Parkinson’s disease, and is doing critical work to provide solutions for these disorders now and in the future. We are very pleased to have helped Dr. Rajeev Kumar, MD and the entire CenExel RMCR team achieve this next step in their growth trajectory,” said Channing Hamlet, Managing Director at Objective, Investment Banking & Valuation and the leader of the Business Services Practice. “We are proud to have had the opportunity to contribute our efforts to this transaction which will strengthen CenExel RMCR’s ability to improve the lives of patients battling movement disorders in Colorado and beyond.”
“CenExel RMCR will continue to be a leader in the movement disorders therapeutic area, providing solutions for families and their loved ones,” said Dr. Kumar, Founder and Principal Investigator at CenExel RMCR. “We’re excited to leverage CenExel’s site network infrastructure and best practices to expand CenExel RMCR’s capabilities and serve more patients impacted by such neurological conditions together.”
About Objective, Investment Banking & Valuation
Objective, Investment Banking & Valuation is a leading investment banking and valuation firm offering M&A Advisory and Valuation Advisory Services for lower middle market companies. Founded in 2006, Objective’s seasoned professionals have collectively executed over 500 M&A advisory engagements and 1,000 business valuations within its five practice groups: Business Services, Consumer, Healthcare & Life Sciences, Manufacturing & Distribution, and Technology. Objective is tenaciously invested in providing world-class, sector-focused advisory services aligned with its clients’ objectives. For more information, please visit www.objectiveibv.com.
About CenExel Clinical Research
CenExel Clinical Research (www.CenExel.com) provides unparalleled medical and scientific support in the design and execution of clinical trials. Our therapeutic area focus and attention to detail assures quality, reliable results and has helped CenExel to consistently achieve and exceed patient recruitment goals. CenExel Centers of Excellence have conducted thousands of studies, the variety and complexity of which have resulted in a vast depth of experience and insight for the Principal Investigators and research staff in each facility. The CenExel Centers of Excellence deliver the engagement, expertise, and results to ensure that their clients achieve their clinical research goals.
—
For Immediate Inquiries:
Channing Hamlet
Managing Director, Investment Banking & Valuation
(310) 570-2721
Disclosure
The above testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.
This news release is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. Principals of Objective Capital are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities.
[/vc_column_text][/vc_column][/vc_row]
